|Bid||0.00 x 900|
|Ask||0.00 x 1100|
|Day's Range||14.40 - 15.22|
|52 Week Range||7.51 - 20.83|
|Beta (3Y Monthly)||1.83|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 5, 2019 - Mar 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.50|
LOS ANGELES-- -- Q2 2019 Record Revenue of $7.7 Million, Up 135% Year over Year and Up 13% from Q1 2019 Outreach Pool of Eligible Members Increases to Approximately 112,000 in August 2019, up 49% from 75,000 at March 31, 2019 Company Reiterates 2019 GAAP Revenue Guidance of $35 Million Company to Host Conference Call at 4:30 pm ET today Catasys, Inc. , a leading AI and technology-enabled healthcare ...
On Wednesday, August 14, Catasys (NASDAQ: CATS ) will report its last quarter's earnings. Here is Benzinga's preview of the company's release. Earnings and Revenue Sell-side analysts are expecting Catasys's ...
Catasys, Inc. (CATS) (“Catasys” or the “Company”), a leading AI and technology-enabled healthcare company, today announced the expansion of its OnTrak-A solution with a leading national health plan into six new states. It is also the first time Catasys will operate in Maryland, Delaware and Ohio, bringing the Company’s total reach to 27 states. Eligible members in Ohio, Tennessee, North Carolina and South Carolina are now able to participate in OnTrak-A, and enrollment will commence in Maryland and Delaware before the end of Q3.
Catasys, Inc. , a leading AI and technology-enabled healthcare company, today announced that the Company will be releasing financial results for its second quarter ended June 30, 2019, after the closing of the stock market on Wednesday, August 14, 2019.
BERKELEY, Calif., and VANCOUVER, British Columbia, Aug. 12, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage.
Catasys (CATS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catasys, Inc. , a leading AI and technology-enabled healthcare company, today announced that Mr. Terren Peizer, the Company’s Chairman and CEO, is scheduled to present at the Canaccord Genuity 39th Annual Growth Conference on Wednesday, August 7, 2019, at 2 p.m.
Catasys, Inc. , a leading AI and technology-enabled healthcare company, today announced the appointment of Mr. Robert L. Rebak to its Board of Directors, replacing Mr.
Nate Pile, editor of Nate's Notes, selected Catasys (CATS) as his top investment idea for 2019. The stock has since risen 105%. Here's his latest update on the health services provider.
Investing can be hard but the potential fo an individual stock to pay off big time inspires us. Not every pick can be...
Catasys, Inc. (CATS) (“Catasys” or the “Company”), a leading AI and technology-enabled healthcare company, today announced that it has been added to the Russell 3000® and 2000® Indexes, effective after the U.S. markets open on Monday, July 1, 2019, as part of the 2019 Russell U.S. Indexes reconstitution. Terren Peizer, Catasys Chairman and CEO, stated, “We are very pleased to have earned our inclusion in the Russell Indexes. The annual Russell Indexes reconstitution captures the 4,000 largest US stocks at the close of the market on May 10, 2019, ranking them by total market capitalization.
Catasys, Inc. , a leading AI and technology-enabled healthcare company, today announced the appointment of Daniel Prewitt as the senior vice president of sales.
Sharon Gabrielson joined the Sharps Compliance board in February 2019. She is a progressive healthcare executive with over 30 years of broad-based leadership experience in the healthcare industry and currently serves as Chair of Global Business Solutions for the Mayo Clinic, where she is responsible for directing domestic and international business development opportunities for the Clinic’s healthcare products and services to the B2B and B2C markets. Previously, Ms. Gabrielson was Vice Chair of Mayo’s Health System Administration, where she oversaw an organization of community-based practices including hospitals, clinics, nursing homes, and home health, which generated approximately $2 billion in revenues. Ms. Gabrielson has served on numerous leadership and management committees at Mayo Clinic, as well as industry boards including for-profit public and private, as well as not-for-profit and community organizations.
When markets have large selloffs and are making new lows, I always like to check out the list of stocks that are making new highs. I do this to find new investment opportunities because I believe that if these stocks perform well in bad markets, they will probably do even better when the markets eventually turn around and are rising.Don't let the "fake news" financial media scare you with their gloom and doom reporting. There is always a bull market somewhere! Coda Octopus Group, Inc. (NASDAQ:CODA) is first one my list. Besides having a really cool name, they make really cool products. This company is in the 3D sonar business.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIt is considered a defense company because they sell a lot of their products to the military. There is no doubt that they are developing some top secret technology for the Navy. Over the past year it is up about 375% and traded at a new all-time new high this month.Biosig Technologies Inc. (NASDAQ:BSGM) also traded at an all-time high this month. The company makes medical devices that improve electrocardiograms. This company actually losses money.It lost about $17 million last year and about $13 million in the year before. I actually looked at the financials going back to 2014 and they have lost money every year since then.Despite the losses some investors clearly think that they will have more profitable prospects in the future. The price of the stock has doubled in price since November and made a new high in May.Catasys Inc. (NASDAQ:CATS) has also lost money every year since 2014 but investors don't seem to care. They must believe that the future prospects for profitability outweigh the current actual losses.Over the past year it has appreciated by about 140%. This company provides data analytics to the healthcare industry and this could explain the reason for the optimism.Data analytics and healthcare are two of the fasting growing industry and Catasys is involved in both of them.Everbridge Inc. (NASDAQ:EVBG) develops software for critical event management. In other words, if something bad happens to a company's computer infrastructure, such as being hacked, their product helps companies deal with it.This company also losses money. In 2016 it lost 68 cents per share, in 2017 it lost 70 cents per share and last year the losses were significantly worse at $1.63 per share.It appears to be headed in the wrong direction but investors don't seem to care. The stock price has appreciated by about 60% over the past year.GW Pharmaceuticals PLC (NASDAQ:GWPH) is a biotechnology company that develops products for the medical marijuana markets. This company is widely followed by Wall Street and has significant institutional investors backing it.Yesterday, Oppenheimer upgraded it to an "outperform" rating and they raised their target price from $191 to $227. The prices of the shares are up about 80% since November and it traded at an all-time high in May.Rent-A-Center Inc. (NASDAQ:RCII) rents things like furniture, electronics, appliances, computers and smartphones. They have retail stores throughout the country.The company has faced some controversy over the years because they charge very high interest rates and their customers are typically lower income earners. Investors apparently do not have an issue with this. The stock price has risen about %160 over the past year.Zynex Inc. (NASDAQ:ZYXI) designs, manufactures, and markets medical devices. They are considered by some to be the market leader in electrotherapy pain management.This type of treatment is an alternative to opioids. Maybe this could help to end the terrible opioid epidemic that is happening across the country.The market capitalization is only $223 million so it would be considered by most to be a small cap or microcap company. Only two Wall Street firms follow this company and they each have buy ratings on it. The price of the company's stock has doubled since August.As of this writing, Mark Putrino did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Stocks to Sell Before They Tank Your Portfolio * Top 7 Dow Jones Stocks of 2019 -- So Far * 5 Low-Priced, High-Potential Tech Stocks to Buy Compare Brokers The post 7 Stocks to Buy That Are Near 52-Week Highs appeared first on InvestorPlace.
Catasys, Inc. , a leading AI and technology-enabled healthcare company, today announced that Mr. Terren Peizer, the Company’s Chairman and Chief Executive Officer, will present at the B.
Catasys, Inc. , a leading AI and technology-enabled healthcare company, today announced that for every day in the month of May, it is sponsoring a health plan member who would otherwise not be able to participate in OnTrak, at no cost to either the member or the health plan.
LOS ANGELES-- -- Q1 2019 Record Revenue of $6.8 Million, Up 256% Year over Year and Up 21% from Q4 2018 Outreach Pool of Eligible Members Increases to Approximately 92,000 in May 2019, up 124% from 41,000 at December 31, 2018 Company Reiterates 2019 GAAP Revenue Guidance of $35 Million Company to Host Conference Call at 4:30 pm ET today Catasys, Inc. , a leading AI and technology-enabled healthcare ...
Catasys, Inc. (CATS) (“Catasys” or the “Company”), a leading AI and technology-enabled healthcare company, today announced that it is expanding the use of its OnTrak solution to help identify and address loneliness. An estimated one in three adults over age 45 suffer from chronic loneliness, according to a 2018 survey by the AARP Foundation. Poor social relationships have been associated with a 29% increase in risk of coronary heart disease and a 32% rise in the risk of stroke, along with increased use of accident and emergency services independent of chronic illness.